PDSB News and Press, PDS Biotechnology Corporation From 11/14/23

PDS Biotechnology Corporation (PDSB) is expected to report $-0.42 for Q3 2023

2023-11-13 13:09:25 ET More on PDS Biotechnology PDS Biotechnology: PDS0101 Being Put To The Test PDS Biotech reports encouraging survival data for HPV 16+ cancer therapy PDS Biotech posts Phase 1/2 data for prostate cancer therapy Seeking Alpha’s Quan...

2023-11-13 09:41:06 ET Major earnings expected before the bell on Tuesday include: Canadian Solar ( CSIQ ) The Home Depot ( HD ) Sea ( SE ) Vodafone Group Public ( VOD ) Workhorse Group ( WKHS ) For further details see: Notable earnings be...

2023-11-09 10:40:49 ET More on PDS Biotechnology PDS Biotechnology: PDS0101 Being Put To The Test PDS Biotechnology (PDSB) Q2 2023 Earnings Call Transcript PDS Biotechnology: Interim Data Reinforces Push Towards Phase 3 Study PDS Biotech posts Phase 1/2 data ...

75% of immune checkpoint inhibitor (ICI) naïve patients remain alive at 36 months; published median overall survival (OS) in similar patients is 7-11 months 12-month survival rate in ICI resistant patients is 72% Median OS in ICI resistant patients is approximately 20 months;...

PRINCETON, N.J., Nov. 07, 2023 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB) (PDS Biotech or the Company), a clinical-stage immunotherapy company developing a growing pipeline of targeted cancer immunotherapies and infectious disease vaccines based on the Company’s propr...

2023-11-01 04:02:35 ET Summary PDSB provided updated interim data from its Versatile-002 study of PDS0101 in early October. While the survival data are strong, there were no responses in checkpoint inhibitor-refractory patients. Versatile-003 is set to get underway in Q4'23. The t...

Combination of PDS0101 and KEYTRUDA ® appears to lead to changes towards a TH1 predominant cytokine profile reported to be associated with improved killer T cell activity Lowered CD8 T cells in peripheral blood after treatment align with previously reported CD8 T cell targeting and a...

2023-10-11 08:56:30 ET More on PDS Biotechnology PDS Biotechnology (PDSB) Q2 2023 Earnings Call Transcript PDS Biotechnology: Interim Data Reinforces Push Towards Phase 3 Study The Prognosis For PDS Biotechnology PDS Biotech updates Phase 2 data for lead asse...

First study of patients with metastatic prostate cancer to evaluate standard-of-care chemotherapy (docetaxel) combined with an antibody drug conjugate (PDS0301). Decrease in prostate specific antigen (PSA) levels was seen in all patients at all three tested doses of PDS0301. The combinati...